CSF levels of tau, β-amyloid1-42 and GAP-43 in frontotemporal dementia, other types of dementia and normal aging

被引:209
作者
Sjögren, M
Minthon, L
Davidsson, P
Granérus, AK
Clarberg, A
Vanderstichele, H
Vanmechelen, E
Wallin, A
Blennow, K
机构
[1] Univ Gothenburg, Sahlgrens Univ Hosp, Inst Clin Neurosci, SE-43180 Molndal, Sweden
[2] Lund Univ, Dept Community Med, S-22100 Lund, Sweden
[3] Malmo Univ Hosp, Neuropsychiat Clin, Malmo, Sweden
[4] Univ Hlth Sci, Dept Geriatr, Linkoping, Sweden
[5] Innogenetics, Ghent, Belgium
关键词
Alzheimer's disease; frontotemporal dementia; vascular dementia; subcortical; while matter; Parkinson's disease; cerebrospinal fluid; GAP-43; tau; beta-amyloid; biochemical marker;
D O I
10.1007/s007020070079
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Cerebrospinal fluid (CSF) levels of tau, beta-amyloid(1-42) and growth-associated protein 43 (GAP-43) were studied in patients with frontotemporal dementia (FTD; n = 17), Alzheimer's disease (AD; n = 60), subcortical white-matter dementia (SWD; n = 24), Parkinson's disease (PD; n = 23) and dysthymia (n = 19) and in age-matched controls (n = 32). CSF-tau was significantly increased only in AD, and CSF-beta-amyloid(1-42) was significantly decreased in AD and SWD as compared to controls, and in AD compared to FTD. CSF-GAP-43 was significantly decreased only in PD. The GAP-43/tau ratio was decreased in all the patient groups except the dysthymia group compared to controls. A positive correlation was found between CSF-GAP-43 and CSF-tau in all groups. The results suggest normal levels of CSF-tau and CSF-beta-amyloid(1-42) in FTD, which will aid in the clinical separation of FTD from AD. In SWD, decreased levels of CSF-beta-amyloid(1-42) suggest concomitant involvement of vascular and amyloid protein mechanisms.
引用
收藏
页码:563 / 579
页数:17
相关论文
共 62 条
[41]   Diagnostic and Statistical Manual of Mental Disorders [J].
Mittal, Vijay A. ;
Walker, Elaine F. .
PSYCHIATRY RESEARCH, 2011, 189 (01) :158-159
[42]   TAU IN CEREBROSPINAL FLUIDS - ESTABLISHMENT OF THE SANDWICH ELISA WITH ANTIBODY SPECIFIC TO THE REPEAT SEQUENCE IN TAU [J].
MORI, H ;
HOSODA, K ;
MATSUBARA, E ;
NAKAMOTO, T ;
FURIYA, Y ;
ENDOH, R ;
USAMI, M ;
SHOJI, M ;
MARUYAMA, S ;
HIRAI, S .
NEUROSCIENCE LETTERS, 1995, 186 (2-3) :181-183
[43]   REDUCTION OF BETA-AMYLOID PEPTIDE(42), IN THE CEREBROSPINAL-FLUID OF PATIENTS WITH ALZHEIMERS-DISEASE [J].
MOTTER, R ;
VIGOPELFREY, C ;
KHOLODENKO, D ;
BARBOUR, R ;
JOHNSONWOOD, K ;
GALASKO, D ;
CHANG, L ;
MILLER, B ;
CLARK, C ;
GREEN, R ;
OLSON, D ;
SOUTHWICK, P ;
WOLFERT, R ;
MUNROE, B ;
LIEBERBURG, I ;
SEUBERT, P ;
SCHENK, D .
ANNALS OF NEUROLOGY, 1995, 38 (04) :643-648
[44]   DEMENTIA OF FRONTAL-LOBE TYPE [J].
NEARY, D .
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 1990, 38 (01) :71-72
[45]  
Risberg J., 1983, FUNCTIONAL RADIONUCL, P151
[46]   VASCULAR DEMENTIA - DIAGNOSTIC-CRITERIA FOR RESEARCH STUDIES - REPORT OF THE NINDS-AIREN INTERNATIONAL WORKSHOP [J].
ROMAN, GC ;
TATEMICHI, TK ;
ERKINJUNTTI, T ;
CUMMINGS, JL ;
MASDEU, JC ;
GARCIA, JH ;
AMADUCCI, L ;
ORGOGOZO, JM ;
BRUN, A ;
HOFMAN, A ;
MOODY, DM ;
OBRIEN, MD ;
YAMAGUCHI, T ;
GRAFMAN, J ;
DRAYER, BP ;
BENNETT, DA ;
FISHER, M ;
OGATA, J ;
KOKMEN, E ;
BERMEJO, F ;
WOLF, PA ;
GORELICK, PB ;
BICK, KL ;
PAJEAU, AK ;
BELL, MA ;
DECARLI, C ;
CULEBRAS, A ;
KORCZYN, AD ;
BOGOUSSLAVSKY, J ;
HARTMANN, A ;
SCHEINBERG, P .
NEUROLOGY, 1993, 43 (02) :250-260
[47]  
Roses Allen D., 1994, Current Opinion in Biotechnology, V5, P663, DOI 10.1016/0958-1669(94)90091-4
[48]  
Sjogren M, 1997, INT J GERIATR PSYCH, V12, P656
[49]  
SKENE JHP, 1981, J NEUROSCI, V1, P419
[50]   A population-based study of tau protein and ubiquitin in cerebrospinal fluid in 85-year-olds: Relation to severity of dementia and cerebral atrophy, but not to the apolipoprotein E4 allele [J].
Skoog, I ;
Vanmechelen, E ;
Andreasson, LA ;
Palmertz, B ;
Davidsson, P ;
Hesse, C ;
Blennow, K .
NEURODEGENERATION, 1995, 4 (04) :433-442